ADMA Biologics said March 27 that end-user demand for Asceniv has risen steadily over the past two-plus years and is now at a record high, as the company pushed back against a March 24 short report from Culper Research.
The company said distributor and direct-customer data show Asceniv inventory days on hand fell from 84 days on Jan. 5, 2026 to 48 days on March 22, 2026, while Bivigam inventory days on hand declined from 87 to 51 over the same period.
Including safety stock, Asceniv inventory days of coverage dropped from 128 days to 90 days, and Bivigam inventory days of coverage fell from 129 days to 92 days.
ADMA said the inventory levels are consistent with industry peers and reflect the long production cycle for its immune globulin products. It also said its distributors typically hold stock above minimum requirements to support immediate administration and guard against supply, manufacturing, testing and regulatory disruptions.
The company said Asceniv is used as a late-line therapy for immune-compromised patients who do not respond to standard immune globulin treatments, and said the product commands premium pricing in that setting.
ADMA also said it received unqualified audit opinions for fiscal 2024 and fiscal 2025, and said it has never sold immune globulin products to any entity controlled by the Grossman family or other related parties. As a result of these announcements, the company's shares have moved -1.09% on the market, and are now trading at a price of $17.31. For more information, read the company's full 8-K submission here.
